Stemline Therapeutics, a biotech developing treatments that target cancer stem cells and tumor bulk, raised $33 million by offering 3.3 million shares (1.0 million more than expected) at $10, the low end of the range of $10 to $12. Stemline Therapeutics plans to list on the NASDAQ under the symbol STML. Aegis Capital Corp. was the sole bookrunner on the deal.
